Trifan, Anca <br/><br/>
Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.  [electronic resource] 

 -  Medicine  Dec 2017 
 - e9271 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1536-5964 
<br/><br/><label>Standard No.: </label>10.1097/MD.0000000000009271  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Naphthylamine<br/>Aged<br/>Aged, 80 and over<br/>Anilides--therapeutic use<br/>Antiviral Agents--therapeutic use<br/>Carbamates--therapeutic use<br/>Cyclopropanes<br/>Drug Resistance, Viral<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Lactams, Macrocyclic<br/>Liver Cirrhosis--drug therapy<br/>Macrocyclic Compounds--therapeutic use<br/>Male<br/>Proline--analogs & derivatives<br/>Prospective Studies<br/>Ribavirin--therapeutic use<br/>Ritonavir--therapeutic use<br/>Sulfonamides--therapeutic use<br/>Sustained Virologic Response<br/>Uracil--analogs & derivatives<br/>Valine